June 29, 2021, Wilmington, MA — Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on future performance. [Read more…]
denovoMATRIX acquires state grant for accelerating development of iPSC scale-up technologies
DRESDEN, Germany, June 28, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, has received a grant from the State Bank of Saxony for the development of microcarriers designed for xeno-free induced pluripotent stem cell culture. The outlook for the technology is for applications in iPSC banking, allogenic therapies, as well as the clean meat industry.
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of iPSC-based Therapies
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies. The deal will enable Catalent to offer the building blocks to scale iPSC-based cell therapies while reducing barriers to entry to the clinic for therapeutic companies and is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have not been disclosed.
Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality
TreeFrog Therapeutics announces the results of two runs of hiPSC amplification in 10L bioreactors at the Annual Meeting of the International Society for Stem Cell Research.
BORDEAUX, France, Jun. 21, 2021 — Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem Cell Research (ISSCR). The data shows the output from two batches with indistinguishable expansion curves, demonstrating a high degree of reproducibility, while cell analysis showed conservation of stem cell quality. [Read more…]
Kite and Shoreline Biosciences to Develop iPSC-Derived Cellular Immunotherapeutics
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
Partnership Follows Kite’s Investment in Shoreline’s Recent Series A Financing
June 17, 2021, SANTA MONICA, Calif. & SAN DIEGO — Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced a strategic partnership to develop novel cell therapies across a variety of cancer targets. [Read more…]
- « Previous Page
- 1
- …
- 157
- 158
- 159
- 160
- 161
- …
- 334
- Next Page »